EssilorLuxottica Société anonyme Valuation
Is ESL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ESL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ESL (€229.35) is trading below our estimate of fair value (€244.06)
Significantly Below Fair Value: ESL is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ESL?
Key metric: As ESL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ESL's PE Ratio? | |
|---|---|
| PE Ratio | 45.4x |
| Earnings | €2.29b |
| Market Cap | €104.10b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.4x |
| Enterprise Value/EBITDA | 20.9x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does ESL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 42.3x | ||
7741 HOYA | 34.4x | 11.4% | JP¥6.8t |
ALC Alcon | 37.6x | 9.8% | CHF 38.6b |
COLO B Coloplast | 39.7x | 12.9% | DKK 200.8b |
COO Cooper Companies | 57.3x | 22.9% | US$20.6b |
ESL EssilorLuxottica Société anonyme | 45.4x | 15.6% | €104.1b |
Price-To-Earnings vs Peers: ESL is expensive based on its Price-To-Earnings Ratio (45.4x) compared to the peer average (42.3x).
Price to Earnings Ratio vs Industry
How does ESL's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: ESL is expensive based on its Price-To-Earnings Ratio (45.4x) compared to the European Medical Equipment industry average (29.8x).
Price to Earnings Ratio vs Fair Ratio
What is ESL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 45.4x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ESL's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €229.35 | €219.05 -4.5% | 10.2% | €263.00 | €173.00 | n/a | 20 |
| Nov ’25 | €217.15 | €218.75 +0.7% | 10.3% | €263.00 | €173.00 | n/a | 20 |
| Oct ’25 | €211.95 | €212.95 +0.5% | 9.3% | €250.00 | €173.00 | n/a | 19 |
| Sep ’25 | €216.30 | €210.55 -2.7% | 7.9% | €235.00 | €173.00 | n/a | 20 |
| Aug ’25 | €211.65 | €210.05 -0.8% | 8.0% | €235.00 | €173.00 | n/a | 20 |
| Jul ’25 | €203.10 | €209.90 +3.3% | 8.8% | €235.00 | €162.00 | n/a | 20 |
| Jun ’25 | €204.75 | €206.95 +1.1% | 8.2% | €229.00 | €162.00 | n/a | 19 |
| May ’25 | €200.90 | €205.89 +2.5% | 8.2% | €229.00 | €162.00 | n/a | 19 |
| Apr ’25 | €209.18 | €201.16 -3.8% | 7.6% | €228.00 | €162.00 | n/a | 19 |
| Mar ’25 | €197.41 | €197.84 +0.2% | 7.4% | €220.00 | €162.00 | n/a | 20 |
| Feb ’25 | €183.59 | €192.54 +4.9% | 7.5% | €215.00 | €162.00 | n/a | 22 |
| Jan ’25 | €181.77 | €193.26 +6.3% | 8.0% | €220.00 | €162.00 | n/a | 22 |
| Dec ’24 | €178.15 | €193.04 +8.4% | 8.2% | €220.00 | €162.00 | n/a | 22 |
| Nov ’24 | €171.29 | €192.76 +12.5% | 8.2% | €220.00 | €162.00 | €217.15 | 22 |
| Oct ’24 | €166.28 | €194.59 +17.0% | 8.5% | €220.00 | €155.00 | €211.95 | 21 |
| Sep ’24 | €174.16 | €194.15 +11.5% | 8.7% | €220.00 | €155.00 | €216.30 | 20 |
| Aug ’24 | €180.01 | €194.50 +8.0% | 8.7% | €220.00 | €155.00 | €211.65 | 20 |
| Jul ’24 | €172.55 | €192.63 +11.6% | 8.4% | €220.00 | €155.00 | €203.10 | 19 |
| Jun ’24 | €165.43 | €191.94 +16.0% | 8.2% | €215.00 | €155.00 | €204.75 | 18 |
| May ’24 | €178.47 | €191.46 +7.3% | 7.8% | €215.00 | €155.00 | €200.90 | 20 |
| Apr ’24 | €166.43 | €186.01 +11.8% | 8.0% | €210.00 | €155.00 | €209.18 | 19 |
| Mar ’24 | €164.00 | €187.69 +14.4% | 8.4% | €210.00 | €155.00 | €197.41 | 19 |
| Feb ’24 | €168.35 | €187.06 +11.1% | 8.7% | €210.00 | €155.00 | €183.59 | 19 |
| Jan ’24 | €169.73 | €184.66 +8.8% | 9.5% | €210.00 | €150.00 | €181.77 | 20 |
| Dec ’23 | €177.90 | €179.98 +1.2% | 9.0% | €205.00 | €150.00 | €178.15 | 19 |
| Nov ’23 | n/a | €179.98 0% | 9.0% | €205.00 | €150.00 | €171.29 | 19 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Siemens Healthineers
€54.9b
Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.
SHL
€48.44
7D
0%
1Y
n/a
Carl Zeiss Meditec
€5.0b
Operates as a medical technology company in Germany, rest of Europe, North America, and Asia.
AFX
€56.40
7D
3.1%
1Y
-31.0%